



## Supporting Information




**Fig. S1. Optimization of modified cpVNT with Alexa Fluor594 labeled ACE2.**

**A.** Fluorescence intensity (voltage output) measured with blood samples in the presence and absence of mouse monoclonal SARS-CoV-2 nAb. **B.** Four different participants' samples: pre-vaccination (Pre-Vac), post 1<sup>st</sup> dose (01-P1, 34-P1) and post 2<sup>nd</sup> dose (P2) were used for optimization of RBD-CBD incubation time and **C.** ACE2-AF594 incubation time. All samples were tested in triplicates. **D.** Comparison of fluorescent intensity between Test spot-T and Control spot-C with 15 post 2nd dose vaccinees' whole blood samples.




**Fig. 2. Signal intensity for negative control and baseline as well as correlation of plasma and whole blood samples with modified cpVNT.**

**A.** Fluorescence intensity (voltage output) measured from 60 pre-vaccination blood samples, red line represents median of the distribution, 1141 mV; which is the value used as NC for % blocking calculation. **B.** Total 31 samples (pre and post vaccination) were measured in the absence of RBD-CBD, where the red line is the median, 230 mV. **C.** A total of 46 matching samples of finger stick and venous blood showed strong correlation (Pearson r: 0.9758, p<0.0001) in percent blocking detection using the modified cpVNT.



**Fig. S3 Biolayer interferometry profiles for RBD-CBD variants with biotinylated ACE2 immobilized on streptavidin biosensors.**

**A.** RBD-CBD alpha, **B.** RBD-CBD beta, **C.** RBD-CBD gamma, **D.** RBD-CBD delta, **E.** RBD-CBD kappa, **F.** RBD-CBD epsilon, **G.** RBD-CBD delta plus, **H.** RBD-CBD eta, **I.** RBD-CBD lambda and **J.** RBD-CBD AD



**Fig. S4 Signal intensity of RBD-CBD variants' response with fluorescence labelled ACE2.**

**A.** The fluorescence intensity (voltage output) of pre vaccination blood sample when tested against wildtype (WT) and RBD-CBD variants of different binding affinity against ACE2. The numbers above each bar indicate fold of increase in intensity as compared to WT. **B.** The nAb percent blocking measured from 34 post 2<sup>nd</sup> dose vaccinated samples (within 3 months) against AD, the hypothetical RBD-CBD.

**Table S1. Fluorescence intensity (voltage output) measured from two batches of ACE2-AF594 with pre vaccine blood samples for negative control calibration.**

ACE2- AF594 Batch	RBD-CBD Concentration (nM)	Fluorescence intensity for NC	# Samples	Fluorescence intensity for baseline	# Samples
1	10	1088.7 ( $\pm 179.8$ )	17	181.1 ( $\pm 18.3$ )	7
2	10	1235.5 ( $\pm 185.9$ )	43	254.1 ( $\pm 25.9$ )	24

**Table S2: Samples used for modified cpVNT-blood in comparison with pVNT, cPass and cpVNT-plasma**

Sample ID	Vaccination status	% Neutralization in pVNT	% Inhibition in cPass	% Blocking cpVNT-blood	% Blocking cpVNT-plasma
0001-V-V05-PV	Pre-Vac		-7.763312	22.94239	
0003-F-V03-PV	Pre-Vac		-17.49623	-18.20988	
0004-V-V01-PV	Pre-Vac	0		19.75356	19.01346
0004-V-V04-PV	Pre-Vac		-2.99429	-7.40E-15	
0004-F-V06-PV	Pre-Vac		-5.805046	12.53561	
0005-V-V01-PV	Pre-Vac		-13.7654	27.02332	
0007-V-V01-PV	Pre-Vac	0	-10.4598	11.35117	11.89958
0008-V-V01-PV	Pre-Vac	0	-14.8892	11.96845	-21.78846
0009-V-V01-PV	Pre-Vac		-8.86967	13.20597	
0011-V-V01-PV	Pre-Vac		-11.27776	-27.88066	
0013-F-V06-PV	Pre-Vac		-5.521211	-12.65432	
0013-F-V08-PV	Pre-Vac	0		8.40192	
0022-F-V01-PV	Pre-Vac		1.500837	-11.34092	
0022-V-V01-PV	Pre-Vac	0.12	11.52455	21.31724	15.95626
0026-F-V01-PV	Pre-Vac		-6.576852	-38.8203	
0027-F-V01-PV	Pre-Vac		3.549902	12.41427	
0030-F-V01-PV	Pre-Vac		7.101754	14.3	
0036-V-V01-PV	Pre-Vac	0		9.84225	11.50885
0042-V-V01-PV	Pre-Vac			12.89438	8.254454
0054V-V01-PV	Pre-Vac			1.646091	-4.238932
0001-F-V09-P1-02W-MD	P1		66.0465	31.893	
0001-V-V12-P1-05W-MD	P1	43.56	72.68333	36.07682	73.514022
0003-V-V06-P1-03W-PF	P1	1.03	44.83542	21.46776	17.1909
0004-V-V10-P1-03W-MD	P1		75.51875	22.39369	
0009-V-V02-P1-03W-PF	P1	3.21	10.31425	28.45651	8.348457

0010-V-V03-P1-01W-MD	P1		-8.83867	22.97668	19.5426
0010-F-V06-P1-03W-MD	P1		89.66134	73.07956	
0011-V-V02-P1-03W-PF	P1		31.8281	34.12209	
0012-V-V01-P1-03W-PF	P1	3.02	41.51574	39.16324	28.42025
0013-F-V09-P1-02W-MD	P1		67.62917	20.78189	
0019-V-V2-P1-03W-PF	P1	37.75	63.88273	27.02332	50.4968
0020-F-V01-P1-04W-PF	P1		81.96858	31.48148	
0022-F-V02-P1-01W-PF	P1		1.500837	10.90535	
0022-V-V04-P1-06W-PF	P1	37.75	71.37292	41.46091	60.19754
0025V-V03-P1-6W-PF	P1			48.76543	53.05427
0045V-V05-P1-5W-PF	P1			61.21399	64.01905
0046V-V01-P1-3W-MD	P1			80.55843	96.97219
0049-V-V01-P1-03W-MD	P1		79.53542	39.47188	52.93668
0052-V-V01-P1-05W-PF	P1	36.48	72.69792	28.01783	54.58287
0053V-V01-P1-5W-PF	P1	44.46	71.42917	38.13443	74.68987
0054-V-V02-P1-03W-PF	P1			43.34705	33.47639
0062V-V01-P1-5W-MD	P1			75.5144	83.94967
0001-V-V16-P2-02W-MD	P2		96.88125	95.81619	99.88242
0002-V-V07-P2-07W-PF	P2		97.30353	104.3553	
0002-V-V09-P2-14W-PF	P2	96.19	96.91042	90.84362	99.58845
0004-F-V12-P2-01W-MD	P2		71.09583	40.9808	
0004-V-V14-P2-02W-MD	P2	97.46	96.775	91.80384	99.94121
0006-V-V01-P2-01W-MD	P2	48.63	91.3985	90.18098	

0007-V-V08-P2-03W-MD	P2	94.56	96.81875	91.02304	95.18118
0009-V-V03-P2-03W-PF	P2	63.7	93.34792	84.22497	
0009-V-V04-P2-12W-PF	P2			56.15305	63.6075
0010-F-V07-P2-01W-MD	P2		94.50406	88.40878	
0024-F-V01-P2-08W-PF	P2		96.54536	85.69959	
0028-F-V01-P2-09W-PF	P2		92.88269	81.44719	
0029-F-V01-P2-05W-PF	P2		81.82083	63.3059	
0034-V-V03-P2-02W-MD	P2	99.64	97.06042	96.46776	99.88242
0046V-V02-P2-3W-MD	P2			94.20439	95.70815
0067V-V01-P2-3W-PF	P2			79.13328	61.02064
<b>Total samples</b>		<b>20</b>	<b>45</b>	<b>58</b>	<b>30</b>

**Table S3: The percent inhibition of WHO International Standard and Reference Panel's plasma measured using cPass™.**

<b>WHO Plasma Standard &amp; References</b>	<b>Neutralizing activity (IU/mL)</b>	<b>% Inhibition measured in cPass</b>
International Standard	1000	94.3 ( $\pm 0.26$ )
International Standard (1:1 dilution)	500	90.6 ( $\pm 0.73$ )
Mid titre	210	78.7 ( $\pm 0.65$ )
Low titre	44	19.0 ( $\pm 3.2$ )
Low titre (1:1 dilution)	22	8.3 ( $\pm 1.4$ )